Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Top Cited Papers
Open Access
- 13 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 22 (1), 1-9
- https://doi.org/10.1186/s13058-020-01284-9
Abstract
Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate alpelisib. Methods Data from 6338 patients with BC was explored across 10 publicly available studies. The primary objective was to evaluate the proportion and distribution of PIK3CA mutations in BC. Secondary objectives were (1) to evaluate in silico the spectrum of PIK3CA mutations in BC that would be captured by the therascreen panel; (2) to evaluate the proportion and distribution of PIK3CA mutations in hormone receptor-positive/HER2-negative (HR+/HER2-), HER2+, and triple-negative BC (TNBC); and (3) to explore the identification of PIK3CA mutations in a cohort of 48 HR+/HER2- advanced BC patients by the Guardant B360 circulating tumor DNA (ctDNA) assay. Results Patients with PIK3CAmut tumors represented 35.7% (2261/6338). Five PIK3CA mutations comprised 73% of all PIK3CA mutations: H1047R (35%), E545K (17%), E542K (11%), N345K (6%), and H1047L (4%). Therascreen gene list would capture 72% of all PIK3CA mutations and 80% of patients with a known PIK3CAmut BC. Among patients with double PIK3CAmut tumors (12% of all PIK3CAmut), the therascreen panel would capture 78% as harboring 1 single PIK3CA mutation, 17% as PIK3CAmut undetected, and 5% as PIK3CA double-mut. PIK3CA mutation rates were lower in TNBC (16%) compared to HR+/HER2 (42%) and HER2+ (31%) BC; however, the distribution of the 4 main PIK3CA mutations across subtypes was similar. Finally, 28% of PIK3CA mutations identified in ctDNA in 48 patients with advanced HR+/HER2- BC were not part of the therascreen panel. Conclusion PIK3CA mutations in BC are heterogenous and similar to 20% of patients with a known PIK3CA mutation, and 95% with a known double PIK3CAmut tumor, would not be captured by the therascreen panel. Finally, the clinical utility of PIK3CA mutations not present in the therascreen companion diagnostic assay or identified by other sequencing-based assays needs further investigation.Keywords
This publication has 31 references indexed in Scilit:
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancerScience Translational Medicine, 2015
- Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolutionNature, 2014
- Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical TrialsMolecular Cancer Therapeutics, 2014
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based TherapyClinical Cancer Research, 2014
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Sequence analysis of mutations and translocations across breast cancer subtypesNature, 2012
- The landscape of cancer genes and mutational processes in breast cancerNature, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- The clonal and mutational evolution spectrum of primary triple-negative breast cancersNature, 2012
- Rare cancer-specific mutations in PIK3CA show gain of functionProceedings of the National Academy of Sciences, 2007